The evolution of targeted intra operative radiotherapy in early breast cancer.

IF 2.8 3区医学 Q3 ONCOLOGY

Journal of Cancer Research and Clinical Oncology Pub Date : 2025-09-10 DOI:10.1007/s00432-025-06294-8

Aparimita Das, Khadeer Abdulkarim, Soirindhri Banerjee, Riya Kurmude, Joecelyn Kirani Tan, Lydia Prusty, Ishika Mahajan, Aruni Ghose, Aaditya Tiwari, Abbas Kassamali, Maryam Hasanova, Pratima Chapagain, Christian A Linares, Jayant S Vaidya, Stergios Boussios

{"title":"The evolution of targeted intra operative radiotherapy in early breast cancer.","authors":"Aparimita Das, Khadeer Abdulkarim, Soirindhri Banerjee, Riya Kurmude, Joecelyn Kirani Tan, Lydia Prusty, Ishika Mahajan, Aruni Ghose, Aaditya Tiwari, Abbas Kassamali, Maryam Hasanova, Pratima Chapagain, Christian A Linares, Jayant S Vaidya, Stergios Boussios","doi":"10.1007/s00432-025-06294-8","DOIUrl":null,"url":null,"abstract":"<p><p>Targeted intraoperative radiotherapy (IORT) delivers a single dose of radiation to a fresh tumour bed immediately after lumpectomy, commonly used to treat early breast cancer (EBC). It is delivered during the same sitting, with improved patient compliance and better sparing of adjacent healthy tissue, compared to conventional adjuvant radiotherapy to the whole breast. The recently published 12-year results (median follow up of 8.6 years) of the TARGIT-A trial offers reliable conclusions, of comparable oncological outcomes with a reduced toxicity profile supporting IORT as a replacement for whole breast external beam radiotherapy (EBRT) for suitable patients with EBC. Reduced need of multiple hospital visits is an added logistic advantage which makes IORT a cost-effective, less painful and cosmetically favourable alternative to standard EBRT, now included in several international guidelines with growing popularity among clinicians worldwide.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"249"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12423025/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00432-025-06294-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Targeted intraoperative radiotherapy (IORT) delivers a single dose of radiation to a fresh tumour bed immediately after lumpectomy, commonly used to treat early breast cancer (EBC). It is delivered during the same sitting, with improved patient compliance and better sparing of adjacent healthy tissue, compared to conventional adjuvant radiotherapy to the whole breast. The recently published 12-year results (median follow up of 8.6 years) of the TARGIT-A trial offers reliable conclusions, of comparable oncological outcomes with a reduced toxicity profile supporting IORT as a replacement for whole breast external beam radiotherapy (EBRT) for suitable patients with EBC. Reduced need of multiple hospital visits is an added logistic advantage which makes IORT a cost-effective, less painful and cosmetically favourable alternative to standard EBRT, now included in several international guidelines with growing popularity among clinicians worldwide.

Abstract Image

查看原文本刊更多论文

早期乳腺癌术中靶向放疗的进展。

靶向术中放疗（IORT）在乳房肿瘤切除术后立即向新肿瘤床提供单剂量放疗，通常用于治疗早期乳腺癌（EBC）。与传统的全乳辅助放疗相比，该疗法在同一坐位进行，患者的依从性提高，邻近健康组织得到更好的保护。最近发表的target - a试验的12年结果（中位随访8.6年）提供了可靠的结论，具有可比较的肿瘤结果，毒性降低，支持IORT替代全乳外束放疗（EBRT）治疗适合的EBC患者。减少多次医院就诊的需要是一个额外的物流优势，这使得IORT成为标准EBRT的一种成本效益高、痛苦少、美观的替代方案，现已被列入一些国际指南，在全球临床医生中越来越受欢迎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cancer Research and Clinical Oncology 医学-肿瘤学

CiteScore

4.00

自引率

2.80%

发文量

577

审稿时长

2 months

期刊介绍： The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses. The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.